Streptozocin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00428 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | relapsing-remitting multiple sclerosis | KG + DL |
| 2 | small cell lung carcinoma | KG + DL |
| 3 | pulmonary blastoma | KG + DL |
| 4 | well-differentiated fetal adenocarcinoma of the lung | KG + DL |
| 5 | hereditary breast ovarian cancer syndrome | KG + DL |
| 6 | primary pulmonary lymphoma | KG + DL |
| 7 | lymphosarcoma | KG + DL |
| 8 | rhabdomyosarcoma (disease) | KG + DL |
| 9 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 10 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 11 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 12 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 13 | hereditary persistence of fetal hemoglobin-sickle cell disease syndrome | KG + DL |
| 14 | sickle cell-hemoglobin c disease syndrome | KG + DL |
| 15 | sickle cell-hemoglobin d disease syndrome | KG + DL |
| 16 | sickle cell-hemoglobin E disease syndrome | KG + DL |
| 17 | sickle cell-beta-thalassemia disease syndrome | KG + DL |
| 18 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 19 | liver sarcoma | KG + DL |
| 20 | lymph node cancer | KG + DL |
| 21 | monocytic leukemia | KG + DL |
| 22 | ovarian clear cell adenocarcinoma | KG + DL |
| 23 | female breast carcinoma | KG + DL |
| 24 | actinic cheilitis | KG + DL |
| 25 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 26 | ovarian mucinous adenocarcinoma | KG + DL |
| 27 | Hodgkins lymphoma | KG + DL |
| 28 | T-cell/histiocyte rich large B cell lymphoma | KG + DL |
| 29 | intravascular large B-cell lymphoma | KG + DL |
| 30 | ovarian endometrioid adenocarcinoma | KG + DL |
| 31 | angular cheilitis | KG + DL |
| 32 | rectum mucinous adenocarcinoma | KG + DL |
| 33 | colon mucinous adenocarcinoma | KG + DL |
| 34 | cervical carcinosarcoma | KG + DL |
| 35 | primary non-gestational choriocarcinoma of ovary | KG + DL |
| 36 | endometrial mucinous adenocarcinoma | KG + DL |
| 37 | villoglandular endometrial endometrioid adenocarcinoma | KG + DL |
| 38 | endometrial mixed adenocarcinoma | KG + DL |
| 39 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 40 | lymphoma, non-Hodgkin, familial | KG + DL |
| 41 | gallbladder mucinous adenocarcinoma | KG + DL |
| 42 | cervical mucinous adenocarcinoma | KG + DL |
| 43 | unclassified myelodysplastic syndrome | KG + DL |
| 44 | rete ovarii adenocarcinoma | KG + DL |
| 45 | classic Hodgkin lymphoma, lymphocyte-rich type | KG + DL |
| 46 | lung colloid adenocarcinoma | KG + DL |
| 47 | mucin-rich endometrial endometrioid adenocarcinoma | KG + DL |
| 48 | secretory uterine corpus endometrioid adenocarcinoma | KG + DL |
| 49 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 50 | ovarian small cell carcinoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.